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Many promising therapeutics are currently awaiting their clinical application. Due to their low capability of cell membrane crossing, these
compounds do not reach their site of action. One way to overcome this problem might be the fusion of these agents to cell-penetrating peptides
(CPP), which are able to shuttle various cargoes across cellular membranes. One disadvantage in using CPP in drug delivery is their low metabolic
stability. The aim of our work was to increase the proteolytic resistance of the CPP hCT(9–32), a truncated C-terminal fragment of human
calcitonin. Thus, we synthesised six modified N-terminally carboxyfluorescein labelled hCT(9–32) derivatives by replacing positions 12 and/or
16 of hCT(9–32) with either N-methylphenylalanine or d-phenylalanine, respectively. By using confocal laser scanning microscopy we showed
that the modifications did neither affect the peptide internalisation efficiency in HeLa nor HEK 293T cells. The metabolic stability of the peptides
was investigated in human blood plasma and HEK 293T cell culture supernatant. To analyse the degradation patterns, we used RP-HPLC and
MALDI-TOF mass spectrometry. However, we found for all of the new derivatives high metabolic stabilities. In blood plasma, the half-lives for
five of the six peptides increased compared to unmodified hCT(9–32). The degradation patterns showed a distinct stabilisation in the N-terminal
part of the modified peptides, in the C-terminal part, we found some cleavage to a minor extent. Furthermore, we studied the conformation of the
peptides by CD spectroscopy and demonstrated that they possess no cell toxicity. Since our metabolically more stable compounds are still able to
pass the cell membrane they provide powerful tools as drug delivery vectors.
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During the last decade the interest in efficient drug delivery
systems increased. Hindered by the lipid bilayer of the cell
membrane the access of most therapeutic substances to their
target site is restricted. Therefore, a lot of work is done in0005-2736/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2005.10.006
Abbreviations: CD, circular dichroism; CF, carboxyfluorescein; CLSM,
confocal laser scanning microscopy; CPP, cell-penetrating peptide; DIC,
diisopropylcarbodiimide; HATU, O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate; hCT, human calcitonin; HOBt, 1-hydro-
xybenzotriazole; MALDI-TOF, matrix assisted laser desorption ionisation-time
of flight; MS, mass spectrometry; RP-HPLC, reversed phase - high performance
liquid chromatography; SPPS, solid phase peptide synthesis; TBTU, O-
(benzotriazol-1-yl)1,1,3,3-tetramethyluronium tetrafluoroborate; TFA, trifluor-
oacetic acid; TFE, trifluoroethanole; XTT, 2,3-bis(methoxy-4-nitro-5-sulfophe-
nyl)-2H-tetrazolium-5-carboxanilide
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1 These authors contributed equally to this work.finding suitable vectors for improving the uptake of such
therapeutics. One goal is the fusion of therapeutic agents (by
covalent coupling or complexation) with cell-penetrating
peptides (CPP). They have the ability to pass the cell
membrane and to transport various hydrophilic substances like
peptides, proteins and oligonucleotides into the cytoplasma
[1,2].
Recently, it was found that human calcitonin (hCT) and its
truncated sequence hCT(9–32) possess cell-penetrating prop-
erties since they are able to internalise into excised bovine
nasal epithelium [3,4]. In further studies, the successful
delivery of certain substances by hCT derived peptides was
demonstrated like the antiproliferative drug daunorubicin [5],
plasmid DNA [6] or the enhanced green fluorescent protein
(EGFP) [7].
One disadvantage in using CPP is their low metabolic
resistance. Once in the bloodstream or in- or outside (human)
cells, they are rapidly degraded. On the one hand this1758 (2006) 347 – 354
http://www
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ensure the successful transport of the cargo to its target. On
the other hand, the metabolic cleavage of the CPP is one
prerequisite for the release of the cargo after internalisation.
Furthermore, the metabolic stability influences the clearance
of CPP and their cell toxicity. Therefore, keeping in mind an
efficient future application in pharmacological fields, the
evaluation of its metabolism is for each carrier peptide an
important factor.
Previously, the metabolic cleavage of hCT(9–32) after
incubation with epithelial models was investigated. Tre´hin et
al. found that an initial degradation of the peptide occurred
mainly in the N-terminal part [8]. Considering that the cargo is
coupled N-terminally to the carrier peptide, its effective
transport inside the cells could be limited due to degradation
by peptidases secreted by the cell layers or located in the cell
membrane. Therefore, the purpose of this study was to develop
hCT(9–32) analogues with improved metabolic stability in the
N-terminal part. Here we demonstrate that our modified peptides
were still able to translocate across cell membranes and that they
had better metabolic stabilities than hCT(9–32) itself.2. Materials and methods
2.1. Materials
Na-Fmoc-protected amino acids, 1-hydroxybenzotriazole (HOBt) and 4-
(2V,4V-dimethyloxyphenyl-Fmoc-aminomethyl)phenoxy (Rink amide) resin and
O-(benzotriazol-1-yl)1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)
were obtained from NovaBiochem (Bad Soden, Germany), diisopropylcarbo-
diimide (DIC) and XTT (2,3-bis(methoxy-4-nitro-5-sulfophenyl)-2H-tetrazoli-
um-5-carboxanilide) from Sigma-Aldrich (Taufkirchen, Germany),
trifluoroacetic acid (peptide synthesis grade) from Riedel-de-Haen. O-(7-
azabenzotriazol-1-yl)-1,13,3-tetramethyluronium hexafluorophosphate
(HATU), thioanisole, p-thiocresole, piperidine, ethandithiole, trifluoroacetic
acid (HPLC grade), menadione (2-methyl-1,4-naphthoquinone), Trypan blue,
glycine and 5(6)-carboxyfluoresceine (CF) were purchased from Fluka
(Taufkirchen, Germany). N,N-dimethylformamide, dichloromethane and di-
methyl ether were obtained from Biosolve (Valkenswaard, The Netherlands).Table 1
Amino acid sequences, molecular masses and half-lives in human blood plasma an
derivatives
Peptides MW [Da]a
Name and sequence calc.
hCT(9–32)
LGTYTQDFNKFHTFPQTAIGVGAP-NH2 2950.4
[f12]-hCT(9–32)
LGTfTQDFNKFHTFPQTAIGVGAP-NH2 2950.4
[f16]-hCT(9–32)
LGTYTQDfNKFHTFPQTAIGVGAP-NH2 2966.4
[f12,16]-hCT(9–32)
LGTfTQDfNKFHTFPQTAIGVGAP-NH2 2950.4
[N-Me-F12]-hCT(9–32)
LGT-N-Me-F-TQDFNKFHTFPQTAIGVGAP-NH2 2964.4
[N-Me-F16]-hCT(9–32)
LGTYTQD-N-Me-F-NKFHTFPQTAIGVGAP-NH2 2980.1
[N-Me-F12,16]-hCT(9–32)
LGT-N-Me-F-TQD-N-Me-F-NKFHTFPQTAIGVGAP-NH2 2978.4
a All peptides are N-terminally labelled with CF.Acetonitrile (ACN) was from Merck (Darmstadt, Germany). N-methylpheny-
lalanine was purchased from Bachem (Weil am Rhein, Germany) and d-
phenylalanine from Iris Biotech (Marktredwitz, Germany).
The following side chain protecting groups were chosen: tert-butyl (tBu)
for Ser, Thr and Tyr; tert-butyloxy (tBuO) for Asp and Glu; trityl (Trt) for Asn,
Gln and His; tert-Butyloxycarbonyl (Boc) for Lys.
For cell culturing the following media and supplements were used:
Dulbecco’s modified eagle medium (DMEM), RPMI 1640 (with l-glutamine),
Dulbecco’s phosphate-buffered saline (PBS) without calcium and magnesium,
fetal calf serum (FCS), l-glutamine, nonessential amino acids and trypsine/
EDTA were obtained from Gibco Life Technologies (Karlsruhe, Germany).
Glucose was purchased from Serva (Heidelberg, Germany). Cell culture flasks
(75 cm2) and 96-well plates were from TPP (Trasadingen, Switzerland). Glass
bottom culture dishes used for the CLSM studies were from MatTek
Corporation (Ashland, USA).
2.2. Peptide synthesis
The peptides were synthesised by automated multiple solid-phase peptide
synthesis (SPPS) (Syro, MultiSynTech, Bochum, Germany) and hand coupling
using the Fmoc-strategy.
The d-phenylalanine modified peptides were obtained by SPPS. In order to
get a peptide amide the Rink amide resin was used. The Fmoc-protected amino
acids were introduced in 10-fold excess by double coupling procedures (236
min) by using in situ activation with DIC and HOBt. The Fmoc removal was
carried out with 40% piperidine in DMF, and two times with 20% piperidine for
5 min.
The introduction of N-methylphenylalanine occurred manually with
activation of TBTU (1 eq) and HOBt (1 eq). The following amino acid was
coupled with HATU (1 eq).
The peptides were N-terminally labelled with CF while still bound to the
resin with fully protected side chains. Coupling was performed using a 10-fold
excess of CF, DIC and HOBt. The overall coupling time was 30 min.
The peptide amides were then cleaved with a mixture of TFA/thioanisole/
thiocresole (90/5/5 v/v) within 3 h. The peptides were precipitated from cold
diethyl ether, collected by centrifugation and lyophilised from water/tert-butyl
alcohol (3:1 v/v). Purification of the peptides was achieved by preparative
HPLC on RP18 column (Waters, 5 Am. 25300 mm) by using a linear gradient
of 20–60% B in A (A=0.1% TFA in water; B=0.08% TFA in ACN) over 45
min and a flow rate of 15 ml min1. Identification was performed by MALDI-
TOF mass spectrometry (Voyager RP, Perseptive Biosystems) and purity was
confirmed by analytical RP-HPLC on a Vydac RP18-column (4.6250 mm; 5
Am/300 A˚) using linear gradients of 10–60% B in A over 30 min and a flow
rate of 0.6 ml min1. For analytical data, see Table 1.d HEK 293T cell culture supernatant of hCT(9–32) and the new synthesised
Half-life [h]
exp. human blood plasma HEK 293T cell
culture supernatant
2952.2 36.2T3.2 650T69
2952.3 51.2T1.7 1637T129
2969.2 51.0T4.9 333T35
2952.5 59.6T7.4 640T47
2967.5 37.2T4.9 565T31
2982.3 53.5T8.2 2438T248
2981.6 126.2T15.9 858T247
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Cells were grown in 75 cm2 culture flasks to confluency at 37 -C, 5% CO2
in a humidified atmosphere. HEK 293T cells were grown in Dulbecco’s
modified eagle medium (high glucose) containing 10% heat-inactivated fetal
calf serum and 1% l-glutamine. HeLa cells were cultured in supplemented
RPMI 1640 with 10% heat-inactivated fetal calf serum.
Heparinised blood was taken from volunteers of our group. After
centrifugation, the supernatant was cooled to 80 -C and samples were used
on demand.
2.4. Metabolism studies in human blood plasma and HEK 293T cell
culture supernatant
The peptides (44 AM) were dissolved in 1.05 ml human blood plasma and
then incubated for 72 h by 37 -C with mechanical shaking (300 rpm). Every
12 h a sample (150 Al) was taken and mixed with 60 Al ACN/ethyl alcohol
(1:1 v/v) for plasma protein precipitation. After centrifugation the solvent was
filtered two times (pore unit 0.45 Am and 0.22 Am).
The metabolism studies in HEK 293T cell culture supernatant were
performed in analogues way. Peptides were dissolved in HEK 293T cell culture
supernatant, incubated as described above and after precipitation and
centrifugation filtered one time (pore unit 0.22 Am).
Identification of the fragments was performed by analytical RP-HPLC on a
Vydac RP18-column (4.6250 mm; 5 Am/300 A˚) using linear gradients of
10–60% B in A over 30 min and a flow rate of 0.6 ml min1. Only the N-
terminally labelled fragments were detected by fluorescence measurements.
Since the concentration of the intact peptide decreased linear to the time
(data not shown) the half-lives of the peptides in human blood and HEK 293T
cell culture supernatant were calculated after linear regression of the data pairs.
Analysis of the peaks was achieved by MALDI-MS studies. Therefore, the
peptides (220 AM) were incubated for 72 h (96 h for [N-Me-F12,16]-hCT(9–
32)) in human blood plasma and after incubation the samples were prepared as
described above. The samples were recorded by analytical RP-HPLC, the
fractions were collected, lyophilised and then analysed by MALDI-TOF-MS.
2.5. Cell viability assay
Cell toxicity of the new peptides was investigated by a XTT based
colorimetric cellular viability assay (n3). The tetrazolium salt XTT is cleaved
by the succinate-tetrazolium reductase system in the mitochondria of
metabolically active cells to a soluble orange formazan dye that is measured
by absorbance at 450 nm. Conversion of the tetrazolium compound is therefore
a direct indicator of cell viability.
HeLa cells were grown to subconfluency in 96-well plates. Culture medium
was removed and 20 and 100 AM solutions of the different CF labelled peptides
(CF was also tested for reference) dissolved in OptiMEM were added to the
cells. After incubation, the peptide solutions were removed, and the cells were
washed three times with OptiMEM. Background was defined by the medium,
and untreated cells were used for negative control, as positive control we
incubated cells with 70% EtOH for 15 min.
The cells were incubated for 5 h under normal growth conditions and cell
viability was subsequently measured by the XTT assay. The XTT solution was
prepared in pre-warmed OptiMEM (1 mg XTT/ml), and 1.8 mg menadione was
dissolved in 1 ml acetone. Prior to use, menadione solution was added to the
XTT solution (10 Al/ml). From this final XTT solution, 50 Al were distributed in
each well and incubated at 37 -C and 5% CO2 for 2 h. Then absorption was
measured at 450 nm (Spectrafluor plus, Tecan). To correct for smudges,
fingerprints, etc., we measured at a reference wavelength of 650 nm.
2.6. CD spectroscopy
The CD spectra were recorded using a JASCO model J720 spectro-
polarimeter over 250–180 nm at 20 -C in a N2 atmosphere. Peptide solutions
were in a concentration range of 30–40 AM. Each measurement was repeated
5 times using a thermostable sample cell with a path of 0.02 cm and the
following parameters: response time of 0.2 s, scan speed of 20 nm/min,sensitivity of 10 mdeg, step resolution of 0.2 nm, and bandwidth of 2 nm. The
CD spectrum of the solvent was subtracted from the CD spectra of the peptide
solutions to eliminate the interference from solvent and optical equipment.
High-frequency noise was reduced by means of a low-path Fourier transform
filter. The ellipticity was expressed as the mean-residue molar ellipticity [h]R
in deg cm2 dmol1.
2.7. Confocal laser scanning microscopy
To investigate the peptide uptake, HeLa and HEK 293T cells were seeded in
glass bottom culture dishes, grown to subconfluency and incubated with the CF
labelled peptides (50 AM) in OptiMEM for 60 and 90 min, respectively. After
incubation, cells were washed two times with ice cold OptiMEM, incubated for
3 min with ice cold Trypan blue (6.5 mM in glycine buffer 1:1 v/v, pH 4.5) for
quenching the external fluorescence and washed subsequently two times with
ice cold PBS (with 1% glucose).
After the washing and quenching steps we inspected immediately in PBS
(with 1% glucose) without fixation using a Leica TCS SP2 AOBS with a PL
APO 63/1.40 oil immersion objective and an Ar (100 mW) 488 nm laser.
Untreated cells were used as negative control, cells incubated with 50 AM CF
were analysed as reference.
3. Results
3.1. Synthesis
Previous investigations about the metabolic stability of
hCT(9–32) revealed that the cleavage sites are located mainly
in the N-terminal part before and after positions Tyr12 and
Phe16 (for peptide sequence, see Table 1) [8]. Recently, we
reproduced this instability at the N-terminus in degradation
experiments using the following two models: human blood
plasma and HEK 293T cell culture supernatant. Since we found
major cleavage sites between positions Tyr12–Thr13 and
Phe16–Asn17, we decided to replace the amino acids in
position 12 and 16 by either d-phenylalanine or N-methylphe-
nylalanine, respectively.
The synthesis occurred both with solid phase peptide
synthesis (SPPS) and manual coupling steps by the Fmoc-
tBu strategy. All peptides were N-terminally labelled with CF.
Finally, all acid labile protecting groups were removed and the
peptides were cleaved from the resin by using TFA. After
preparative purification by RP-HPLC and analysis by MALDI-
TOF-MS, six novel hCT derivatives were obtained. An
overview over all new peptides is given in Table 1.
3.2. CD spectroscopy
The conformation of the new peptides was investigated in
aqueous solution (pH 7) as well as in 30% TFE solution by
using CD spectroscopy. As shown in Fig. 1, all peptides adopt
random coil structures in buffer. The observed minima were
around 199 nm. Contrarily, the minima of [N-Me-F16]-hCT(9–
32) and [N-Me-F12,16]-hCT(9–32) were red-shifted to 190 nm.
With the addition of TFE, hCT(9–32) adopts an a-helical
conformation that consists of two negative bands at 205 nm
and 225 nm and one positive peak at 194 nm. This is in
agreement to previously reported data [9] and resembles that
of full length hCT [10]. The d-phenylalanine modified
peptides behave very similar to hCT(9–32) and show spectra
Fig. 1. CD spectra of the CF labelled hCT analogues in aqueous phosphate buffer (pH 7.4) (A, B) and aqueous phosphate buffer (pH 7.4) with 30% TFE (C, D).
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nm and a maximum around 191 nm. In contrast, the spectra
of the N-methylphenylalanine modified peptides are more
different among each other with minima around 203 nm and
218/225 nm and a maximum around 190/194 nm pointing as
well to the formation of a-helices. Interestingly, both [f12]-
hCT(9–32) and [N-Me-F12]-hCT(9–32) resemble in their
structural behaviour hCT(9–32), whereas [f16]-hCT(9–32)
and [N-Me-F16]-hCT(9–32) adopt the similar conformation
to their double modified counterparts [f12,16]-hCT(9–32) and
[N-Me-F12,16]-hCT(9–32).
3.3. Internalisation studies
We confirmed the effective uptake of the CF labelled
peptides by confocal laser scanning microscopy studies using
HEK 293T and HeLa cells. Fig. 2 illustrates the entry of the CF
labelled compounds in HeLa cells after 60 min incubation time
(37 -C; incubation with free CF was for control and with
hCT(9–32) as reference). In fact, all variants were still able to
cross the cell membrane, thus the structure modification did not
affect the translocation into the cytoplasma. In the same way,
the internalisation in HEK 293T cells was determined andagain, the substances were found to translocate into the
cytoplasma (data not shown).
3.4. Cell viability
Cytotoxicity of the compounds was checked by a colori-
metric cell viability assay [11]. HeLa cells were incubated for 5
h with the modified peptides at concentrations of 20 AM and
100 AM. Fig. 3 demonstrates that the peptides showed no
relevant cytotoxic effects on the cells. This is in agreement to
previously reported data [12]. Incubation with CF (20 AM and
100 AM) did also not affect the cell viability. Further, no
significant differences between the higher or lower concentra-
tions were observed.
3.5. Metabolic stability of the peptides in human blood plasma
and HEK 293T cell culture supernatant
The enzymatic stability of the new hCT derivatives was
investigated by using two models as read-out systems: human
blood plasma and HEK 293T cell culture supernatant. The
feasibility of these two systems for our studies was proved
since we could well reproduce the data of Tre´hin et al.
Fig. 2. Cellular uptake of the stabilised peptides in HeLa cells. Cells were incubated with the peptides and CF, respectively, at a final concentration of 50 AM at 37 -C
for 60 min (C–F, and H) and 90 min (A, B, G). Washing with Trypan blue quenched remaining external CF fluorescence. Subsequently, the cells were inspected
without fixation. (A) CF only, (B) CF-hCT(9–32), (C) CF-[f12]-hCT(9–32), (D) CF-[f16]-hCT(9–32), (E) CF-[f12,16]-hCT(9–32), (F) CF-[N-Me-F12]-hCT(9–32),
(G) CF-[N-Me-F16]-hCT(9–32), and (H) CF-[N-Me-F12,16]-hCT(9–32). Each scale bar is 20 Am.
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compounds were incubated in these two media and at certain
time points samples were taken and analysed by RP-HPLC.
The half-lives were evaluated as described in the Experimental
section. In Table 1 are shown the calculated values. Generally,
we found a higher metabolic stability of all new compounds
compared to unmodified hCT(9–32). The highest half-life in
human blood plasma of about 126 h was calculated for the N-
methylphenylalanine modified peptide [N-Me-F12,16]-hCT(9–
32), whereas the other peptides showed about one half lower
values ranging between 51 and 59 h. In contrast, incubating the
peptides with HEK 293T cell culture supernatant showed only
minor degradation. Nevertheless, we observed the same trend
as in human blood plasma, all peptides (except [f16]-hCT(9–
32)) were more stable than hCT(9–32). In the case of the N-
methylphenylalanine modified substances the most stableFig. 3. Relative cell viability of HeLa cells incubated with different concentrations
(black column) was set 100%. Striped columns represent a peptide concentration ocompound was again the one with the exchange at both
positions 12 and 16 and in the case of the d-phenylalanine
modified peptides it was [f12]-hCT(9–32).
3.6. Degradation pattern
Additional degradation experiments should help to clarify
the fragmentation pattern. For analysis of the metabolites the
modified peptides were incubated with human blood plasma
for 72 h (96 h for [N-Me-F12,16]-hCT(9–32)) and fractionated
by RP-HPLC. Since the peptides were labelled at the N-
terminus, only the fragments possessing the CF label could be
detected. Fig. 4A shows typical HPLC chromatograms of
hCT(9–32) (upper panel) and [N-Me-F12,16]-hCT(9–32) (low-
er panel). The collected HPLC peak fractions were further
analysed by MALDI-TOF mass spectrometry (for example, seeof the stabilised peptides at 37 -C for 5 h. The cell viability of untreated cells
f 20 AM and grey columns 100 AM.
Fig. 4. (A) RP-HPLC chromatographs of CF labelled hCT(9–32) (up) and CF labelled [N-Me-F12,16]-hCT(9–32) (bottom) after metabolic degradation in human
blood plasma. Most of the N-terminal cleavage sites in hCT(9–32) were stabilised in the modified peptide. (B) MALDI-TOF mass spectra of the metabolites of CF-
labelled [N-Me-F12,16]-hCT(9–32) after degradation in human blood plasma. The peaks represent [M+H]+.
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corresponded in most cases to [M+H]+. The suggested
cleavage sites of the modified peptides are depicted in Fig. 5.
As can be seen, the fragment hCT(9-17) is found for all
peptides after degradation.
For the compound [f12,16]-hCT(9–32), this cleavage site was
also detected but the amount of the hCT(9-17) fragment was not
as high as for the other peptides. Interestingly, both the d-Phe
modification at position 12 and at position 16 stabilise the
peptide at position 12. But [f12]-hCT(9–32) differs in its
degradation pattern since it was also degraded before and after
Phe16.
The N-methylphenylalanine modified peptides showed
similar cleavage patterns, they all were cleaved off after
position Asn17 and His20. [N-Me-F12]-hCT(9–32) was addi-
tionally cleaved off between positions Thr13–Gln14. ThisFig. 5. Scheme of suggested metabolic cleavage sites of CF labelled modified
hCT analogues after incubation with human blood plasma. Different colours of
the arrows indicate the amount of detected metabolites as analysed by the
peak intensity of the RP-HPLC chromatographs; black>grey> light grey.
X=N-methylphenylalanine.degradation was prevented by the amino acid replacement at
position 16 with N-methylphenylalanine.
All peptides were degraded in the C-terminal part between
Gln24–Thr25 and Ala26–Ile27. Nevertheless, as illustrated in
Fig. 5, the degradation in the C-terminal part occurred only to a
minor extent.
4. Discussion
Since an increasing number of therapeutics like oligonu-
cleotides, peptides and proteins are not able to penetrate
biological membranes due to their hydrophilic nature and
molecular size, their utility for both the ‘‘classical pharmacy’’
and the growing field of gene and protein therapy remains poor.
One possibility to increase the bioavailability of such com-
pounds is their fusion to suitable carrier molecules, e.g. cell-
penetrating peptides, that are able to shuttle various cargoes
across cellular and epithelial barriers. During the last years, a
lot of research was done to identify and investigate several cell-
penetrating peptides like penetratin [13], HIV-Tat protein
derived peptides [14], MPG [15], transportan [16] or hCT
derived peptides [17]. However, one disadvantage in using
CPP is their low metabolic stability. The peptide–cargo
complex should be metabolically stable until the site of action
is reached, here the active cargo should be released effectively
and after that an efficient clearance of the CPP is important to
prevent local or systemic toxicity.
A number of studies demonstrated the potential of hCT-
derived peptides as appropriate drug delivery vectors, since
they were used to efficiently shuttle several cargoes into
various cell types [3–7]. However, Trehin et al. investigated
the metabolic stability of several C-terminal hCT fragments
when in contact with three epithelial models: Calu-3, MDCK
and TR146 [8]. In the presence of all three cell models,
hCT(9–32) was observed to be susceptible to higher rates of
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terminal site, namely around the amino acid positions Tyr12 and
Phe16.
Our aim was to improve the enzymatic resistance of hCT(9–
32) in order to increase its efficiency as drug carrier. To achieve
this purpose, we modified hCT(9–32) at positions Tyr12 and/or
Phe16 by replacing d-phenylalanine and N-methylphenylala-
nine, respectively. Both modifications should lead to a metabolic
stabilisation of the peptide. In case of an N-methylation, this
should be due to a decrease in steric accessibility for proteolytic
enzymes; using non-physiological d-amino acids, the probable
incompatibility with native enzymes is taken for advantage.
Indeed, it was shown that a CPP composed of d-amino acids
was no longer subject to any metabolic degradation [18]. Due to
the higher costs of commercially available d-tyrosine and N-
methyltyrosine position 12 was replaced with N-methylated
phenylalanine and d-phenylalanine, too, because of the struc-
tural similarity of tyrosine and phenylalanine, disadvantageous
effects were not expected after the exchange of tyrosine to the
phenylalanine derivative.
We investigated the metabolic stability of our modified
hCT(9–32) derivatives in contact with human blood plasma.
There exist several examples in the literature describing the use
of human blood as protease source to estimate the in vivo
peptide stability [18–20]. Besides, the feasibility of this system
for our studies was demonstrated since we were able to
reproduce the data of Tre´hin et al. for hCT(9–32). Further-
more, the degradation of the new peptides was determined in
HEK 293T cell culture supernatant because this cell-line is
used for most of our research studies.
As was expected, the modifications at position 12 and/or 16
increased the metabolic stability in blood plasma as well as in
HEK 293T cell supernatant compared with unmodified
hCT(9–32) in nearly any case (see also Table 1). Analysing
the metabolites after incubating with blood plasma proved that
the modifications stabilise the peptides in the replaced amino
acid positions. Through the modifications, there appeared a
new fragment by the cleavage between positions Asn17–Lys18
that was found in the cleavage pattern of every new peptide. In
addition, we detected metabolic cleavage in the C-terminal site.
Since this occurred only to a minor extent, it is probably not
worth to stabilise this part of the peptides. The enormous
stability of the peptides in HEK 293T cell supernatant suggests
that they were almost protected from degradation. Whether this
finding is due to low protein content has to be elucidated. But
still, the trend was the same as in blood plasma and evidences
once more the higher metabolic stability of the new peptides.
Our CD spectroscopic measurements revealed for all
peptides a random coil conformation in aqueous solution and
a transformation of the peptides into an a-helical structure in
the presence of TFE. This is in agreement to previously
reported data [9]. The tested peptides were still able to
internalise into HeLa and HEK 293T cells as proven by CLSM
studies. Furthermore, there were no qualitative differences
between hCT(9–32) and its new derivatives concerning the
cell uptake of the peptides. Obviously, the translocation
efficiency of the substances was not abolished by themodifications. Moreover, the pictures displayed a punctuated
intracellular distribution of the peptides. This is due to an
endocytotic uptake mechanism that was already demonstrated
for hCT(9–32) by previous CLSM experiments [7]. More
recently, for the branched hCT derivative hCT(9–32)-br a
lipid-raft mediated endocytosis was proven [21]. However,
quantitative investigations of the cellular uptake are outstand-
ing. It is likely that an improved metabolic stability could entail
an increase in uptake efficiency.
In conclusion, we synthesised six new derivatives of the
CPP hCT(9–32) that were more metabolically stable compared
to hCT(9–32) in the two investigated systems. Further, we
could show that the hCT(9–32) analogues were indeed
stabilised in their N-terminal part as was suggested by our
thesis. Since the capability to cross the cell membrane was not
abolished and cell toxicity was not monitored these hCT-
derived CPP could provide promising drug delivery vectors of
a new generation.
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